Associated Papers
Ameloblastoma Displays Primary Cilia Maintenance and CEP164 Overexpression.
Miyazaki R et al.
Journal of Dental Research, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
41556616 (PubMed )
Supplement: PRO-35-e70422-s002.xlsx › Table_S1
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Tsao AS et al.
Jco Precision Oncology, 2025
41066729 (PubMed )
Supplement: protocol2_PO-25-00119.pdf
Hedgehog signalling pathway inhibitors in the treatment of basal cell carcinoma: an updated review.
Markota Cagalj A et al.
Journal of Drug Targeting, 2025
Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.
Hoashi T et al.
International Journal of Molecular Sciences, 2022
Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer.
Nicheperovich A et al.
Journal of Personalized Medicine, 2022
Characterization of colibactin-associated mutational signature in an Asian oral squamous cell carcinoma and in other mucosal tumor types.
Boot A et al.
Genome Research, 2020
32661091 (PubMed )
Supplement: supp_gr.255620.119_Supplemental_Table_S2.xlsx › Sheet1
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A et al.
Bmc Cancer, 2018
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.
Bakshi A et al.
Molecular Carcinogenesis, 2017
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ et al.
Cancer Cell, 2015
Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX et al.
Cancer Cell, 2015
Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.
Reifenberger J et al.
Cancer Research, 1998
Select a paper to view details